Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial

The Lancet

Volumn 371, Issue 9629, 2008, Pages 2019-2025

  Frech, Sarah A ^a   DuPont, Herbert L ^b   Bourgeois, A Louis ^c   McKenzie, Robin ^c   Belkind Gerson, Jaime ^d   Figueroa, Jose F ^e   Okhuysen, Pablo C ^e   Guerrero, Norma H ^f   Martinez Sandoval, Francisco G ^g   Meléndez Romero, Juan HM ^g   Jiang, Zhi Dong ^b   Asturias, Edwin J ^c   Halpern, Jane ^c   Torres, Olga R ^c   Hoffman, Ana S ^c   Villar, Christina P ^a   Kassem, Raniya N ^a   Flyer, David C ^a   Andersen, Bo H ^a   Kazempour, Kazem ^h   Breisch, Sally A ^h   Glenn, Gregory M ^a,c   more..

^a IOMAI Corporation   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f Hospital Jardines de Guadalupe   (Mexico)

^g UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^h Amarex Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI VACCINE; HEAT LABILE TOXIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; MALAISE; PHASE 2 CLINICAL TRIAL; PREVENTION AND CONTROL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN PIGMENTATION; TRAVELLER DIARRHEA; VACCINATION;

EID: 44949230030     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60839-9     Document Type: Article

References (27)

1. Black R. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 12 suppl 1 (1990) S73-S79
2. World Health Organization. New frontiers in the development of vaccines against enterotoxigenic (ETEC) and enterohaemmorrhagic (EHEC) E coli infections. Wkly Epidemiol Rec 74 (1999) 98-101
3. Bouckenooghe A., Jiang Z., De La Cabada F., Ericsson C., and DuPont H. Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med 9 (2002) 137-140
4. Glenn G., Flyer D., Ellingsworth L., et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 6 (2007) 809-819
5. Glenn G., Villar C., Flyer D., et al. Safety and immunogenicity of an ETEC vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 75 (2007) 2163-2170
6. McKenzie R., Bourgeois A., Frech S., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25 (2007) 3684-3691
7. Freytag L., and Clements J. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol 236 (1999) 215-236
8. Steffen R., Castelli F., Nothdurft H.D., Rombo L., and Zuckerman N.J. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med 12 (2005) 102-107
9. Qadri F., Ahmed T., Ahmed F., Begum Y., Sack D., and Svennerholm A. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: Dosing studies in different age groups. Vaccine 24 (2005) 1726-1733
10. Sack D., Shimko J., Torres O., et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 25 (2007) 4392-4400
11. Steinsland H., Valentiner-Branth P., Gjessing H., Aaby P., Mølbak K., and Sommerfelt H. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet 362 (2003) 286-291
12. Dupont H., Haynes G., Pickering L., Tjoa W., Sullivan P., and Olarte J. Diarrhea of travelers to Mexico. Relative susceptibility of United States and Latin American students attending a Mexican University. Am J Epidemiol 105 (1977) 37-41
13. Black R., Merson M., Rowe B., et al. Enterotoxigenic Escherichia coli diarrhoea: acquired immunity and transmission in an endemic area. Bull World Health Organ 59 (1981) 263-268
14. Clemens J., Sack D., Harris J., et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158 (1988) 372-377
15. Peltola H., Siitonen A., Kyrönseppa H., et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338 (1991) 1285-1289
16. Scerpella E., Sanchez J., Mathewson I., et al. Safety, immunogenicity, and protective efficacy of the whole-cell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea. J Travel Med 2 (1995) 22-27
17. Wiedermann G., Kollaritsch H., Kundi M., Svennerholm A., and Bjare U. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). J Travel Med 7 (2000) 27-29
18. Look J., Butler B., Al-Khalili M., et al. The adjuvant patch: a universal dose sparing approach for pandemic and conventional vaccines. BioPharm International: guide to vaccine development and manufacture 20 suppl (2007) 34-45
19. Jiang Z., Lowe B., Verenkar M., et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 185 (2002) 497-502
20. Adachi J., Jiang Z., Mathewson J., et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 32 (2001) 1706-1709
21. Jiang Z., Mathewson J., Ericsson C., Svennerholm A., Pulido C., and DuPont H. Characterization of enterotoxigenic Escherichia coli strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992-1997. J Infect Dis 181 (2000) 779-782
22. Taylor D., Bourgeois A., Ericsson C., et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 74 (2006) 1060-1066
23. Bourgeois AL, Halpertn J, Grahek S, et al Vaccination of travelers to Guatemala (GU) and Mexico (MX) with an oral killed vaccine (OKV) for enterotoxigenic E coli (ETEC): Impact of vaccine "take" on risk of ETEC disease and infection with enteric pathogens. 4th International Conference on Vaccines for Enteric Diseases (VED 2007). Lisbon, Portugal. April 25-27, 2007.
24. Allen K., Randolph M., and Fleckenstein J. Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains. Infect Immun 74 (2006) 869-875
25. Berberov E., Zhou Y., Francis D., Scott M., Kachman S., and Moxley R. Relative importance of heat-labile enterotoxin in the causation of severe diarrheal disease in the gnotobiotic piglet model by a strain of enterotoxigenic Escherichia coli that produces multiple enterotoxins. Infect Immun 72 (2004) 3914-3924
26. Zhang J., Zhongkai S., Fan-kun K., et al. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect Immun 74 (2006) 3607-3617
27. Crane J., Choudhari S., Naeher T., and Duffey M. Mutual enhancement of virulence by enterotoxigenic and enteropathogenic Escherichia coli. Infect Immun 74 (2006) 1505-1515